First, it was our gas stoves. Now washers and tumble dryers join the eco-menaces, spewing microplastics into our water and air. Is it time to rethink our laundry habits? (Spoiler alert: probably not).

An excellent new tool that uses a technology called microindentation can measure the health of bone tissue directly and safely.

Is Big Pharma crying wolf over Medicare's new drug pricing negotiations? Will diminished revenue from Medicare negotiating their cost of drugs, and other drug pricing controls, result in reduced research and development (R&D) and fewer innovative drugs coming to market? But let's not kid ourselves — this narrative conveniently ignores the labyrinthine economics of drug pricing and innovation.

Last month, a Delaware judge undid the 30 years of progress the law has made in excluding junk science in the courtroom.

Despite the staggering amounts Americans spend annually, the latest study involving nearly 400,000 participants suggests those colorful multivitamins might be more of a wallet-drainer than a life-saver.

Seventeen people in the U.S. die each day waiting for an organ transplant that never comes, while over 100,000 linger on the transplant list. Lars Larson and I dive into the crux of the issue: our organ transplant system, as government-run as it gets, is plagued by inefficiency, inconsistency, and a distinct lack of accountability. There are solutions, however.

This week, two tales of Chinatown's lore,
One on ultra-processed media we abhor,
And a tribute to a food fav, the potato.

A recent Supreme Court decision allowing the continued sale of the abortion drug, Mifepristone, was not based on FDA approval of the drug. Nor was it a ratification of the FDA’s relaxing prescription requirements. Rather, the Court decided the plaintiffs did not have “standing” to sue.  With that determination, they didn’t need to enquire further into the argument's merits - and tossed the case.

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but clearly there's more to do.

The Supreme Court is poised to decide a case that may seriously restrict the authority of federal regulatory agencies. Some legal observers say the decision could put power-hungry bureaucrats in their place, though others maintain the ruling could force judges and legislators to make scientific determinations they aren't qualified to make. Legal scholar Dr. Barbara Billauer joins us to help make sense of the "Chevron deference."